In de novo DLBCL, the frequencies of TET2 mutations were reported to be 5/48 (10.4%) and 9/27 (33%), and those of DNMT3A mutations 0/48 (0%) and 3/27 (11.1%) (p < 0.05 in both comparisons) in EBV− and EBV+ DLBCL, respectively [111]. The gene discussed is DNMT3A; the disease is diffuse large B-cell lymphoma.